Pharsight

Xopenex Hfa generic

Xopenex Hfa is an asthma medication, primarily used for the treatment and prevention of bronchospasm. It is owned by Sunovion and was first authorized for market use on March 11, 2005. The drug has a total of 2 drug patents, out of which 1 has already expired. The active ingredient in Xopenex Hfa is levalbuterol tartrate.

When will Xopenex Hfa generic be available?

The last patent of Xopenex Hfa, US7256310 titled 'Levalbuterol salt', is set to expire on October 8, 2024. This will trigger the availability of Xopenex Hfa generic drugs in the market. The earlier patent, US8765153, has already expired.

Xopenex Hfa uses

Xopenex Hfa, with its active ingredient levalbuterol tartrate, is used to prevent and treat bronchospasm or asthmatic symptoms. This is common in conditions such as asthma and chronic obstructive pulmonary disease. It works by relaxing and opening air passages in the lungs, making it easier to breathe.

Xopenex Hfa patent expiration

Xopenex Hfa is protected by 2 patents, with the latest one, 'Levalbuterol salt' under US7256310, set to expire on October 8, 2024. This will make way for the release of Xopenex Hfa generic. The other patent, US8765153, has already expired. Below are the details of the patent:

EPO Oppostions filed on Xopenex Hfa

Xopenex Hfa dosage

Want to ask something?